Drugs / SY-007
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04891913 | Jul → Dec 2023 | ischemic stroke | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Suspended | No outcome recorded |
| Phase 1 | NCT04111523 | Mar 2019 → May 2020 | stroke disorder | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04891913 ↗ |
| Route | Intravenous | “Intravenous Injection” NCT04111523 ↗ |